Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter open-label phase II study of SGB-9768 in complement-mediated glomerular diseases
CTR20250104Phase 2Active
- Sponsor
- SanegeneBio
- Start
- Jan 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of SGB-9768 in IgA nephropathy (IgAN), Complement 3 glomerulopathy (C3G) and membranoproliferative glomerulonephritis (MPGN) (3 cohorts), sponsored by SanegeneBio. Primary endpoint: Change in 24-hour urinary protein-to-creatinine ratio (UPCR) from baseline at week 24. Started Jan 2025; status: active.
02
Drugs
SGB-9768
03
Conditions
IgA nephropathy (IgAN)Complement 3 glomerulopathy (C3G)membranoproliferative glomerulonephritis (MPGN)
Beyond the preview
Go deeper on CTR20250104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250104.